昂利康拟定增募资11.6亿元，投向创新药研发及产业化项目

Core Viewpoint - The company, Anglicon, plans to raise 1.16 billion yuan through a private placement of A-shares to fund innovative drug research and industrialization projects [2] Group 1: Fundraising and Purpose - The company aims to expand its funding sources through the issuance of A-shares [2] - The raised funds will accelerate the research and development process of innovative drugs [2] - The initiative is expected to enhance the company's new product pipeline and create new profit growth points [2] Group 2: Strategic Benefits - Successful implementation of the project will strengthen the company's research and innovation capabilities [2] - The move is anticipated to improve the company's overall strength and market positioning in the innovative drug sector [2]